CC-220-NHL-001 A Phase 1/2, Multicenter, Open-Label Study to Assess Safety, Pharmacokinetics, and preliminary efficacy of CC-220, alone and in combination with an anti-CD20 Monoclonal Antibody (MAB) in subjects with relapsed or refractory Lymphomas (Aktiv)
CYTB323A12101 Phase I/II, open label, multicenter study of rapcaptagene autoleucel in adult patients with CLL/SLL, 3L+ DLBCL, ALL and 1L HR LBCL (Aktiv)